Article Text

Download PDFPDF

Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion
  1. Matthias Preusser1,
  2. Frank Winkler2,3,
  3. Manuel Valiente4,
  4. Christian Manegold5,
  5. Elizabeth Moyal6,
  6. Georg Widhalm7,8,9,
  7. Jörg-Christian Tonn10,
  8. Christoph Zielinski1
  1. 1 Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Centre, Medical University Vienna – General Hospital, Vienna, Austria
  2. 2 Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
  3. 3 Clinical Cooperation Unit Neuro-oncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
  4. 4 Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  5. 5 Medical Faculty Mannheim, University of Heidelberg, Mannheim, Baden-Württemberg, Germany
  6. 6 Radiation Oncology Department, Radiobiology team 11, UMR1037 INSERM, Institut Universitaire du Cancer de Toulouse Oncopole, Centre de Recherche contre le Cancer, Toulouse, France
  7. 7 Department of Neurosurgery, Medical University of Vienna (MUV), Vienna, Austria
  8. 8 Department of Neurosurgery, University of California San Francisco (UCSF), San Francisco, USA
  9. 9 Comprehensive Cancer Center–Central Nervous System Tumours Unit (CCC-CNS), Medical University Vienna (MUV), Vienna, Austria
  10. 10 Department of Neurosurgery, Ludwig-Maximilians University, Munich-Grosshadern, Germany and German Cancer Consortium (DKTK) at the German Cancer Research Centre (DKFZ), Heidelberg, Germany
  1. Correspondence to Professor Matthias Preusser; matthias.preusser{at}meduniwien.ac.at

Abstract

This article is the result of a round table discussion held at the European Lung Cancer Conference (ELCC) in Geneva in May 2017. Its purpose is to explore and discuss the advances in the knowledge about the biology and treatment of brain metastases originating from non-small cell lung cancer. The authors propose a series of recommendations for research and treatment within the discussed context.

  • biology and treatment of brain

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This initiative is sponsored by AstraZeneca through the provision of an unrestricted educational grant. AstraZeneca has had no influence over the content other than a review of the paper for medical accuracy. The participants/authors received an honorarium for their participation from BMJ.

  • Competing interests MP: Research support from Boehringer-Ingelheim, GlaxoSmithKline, Merck Sharp and Dohme and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca and AbbVie. FW: Research support from Boehringer Ingelheim, Genentech and Roche. Honoraria for lectures, consultation and advisory board participation from UCB, Roche and Boehringer Ingelheim. CM: Honoraria from Lilly and Boehringer Ingelheim. EM: Research support from AstraZeneca, Merck KGaA, advisory board participation from Merck KGaA. CZ: Honoraria from Ariad, Novartis, Boehringer Ingelheim, Roche and AstraZeneca.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.